China-based Ascletis Pharma Inc. (HKG: 1672) has announced encouraging results from a study on its in-house developed drug candidate, ASC47, which is designed to achieve weight loss without compromising muscle mass. The study combined ASC47 with semaglutide in a diet-induced obesity (DIO) mouse model, demonstrating superior weight loss effects compared to semaglutide alone.
Superior Weight Loss Effects of ASC47 Combination Therapy
In a head-to-head comparison within the DIO mouse model, the low-dose combination therapy of ASC47 (3 mg/kg, subcutaneous injection, once every four weeks) and semaglutide (30 nmol/kg, subcutaneous injection, once daily) showed better weight loss effects than semaglutide alone. The combination therapy resulted in a 36.2% weight loss, compared to 23.1% with semaglutide alone, representing an additional 56.7% weight loss.
ASC47: A Selective Agonist for Targeted Weight Loss
ASC47 is a fat-targeted thyroid hormone receptor beta (THR β) selective small molecule agonist capable of mediating adipose tissue thermogenesis through uncoupling protein-1 (UCP-1). This mechanism has the potential to achieve weight loss without muscle loss, making it a promising candidate for obesity treatment.
Clinical Studies and Upcoming Milestones
Interim results from a Phase I single dose escalation study for ASC47 in subjects with elevated LDL-C levels in Austria have been disclosed. The drug is also undergoing a clinical study in obesity in Australia, with top-line data from the Phase IIa study expected during the second quarter of 2025. These upcoming milestones will provide further insights into the efficacy and safety profile of ASC47.-Fineline Info & Tech
